Travere Therapeutics, Inc. TVTX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +28.92%
- 1 year
- +40.10%
- Open
- 50.47
- Prev close
- 50.39
- Mkt cap
- 4.64B
- Vol
- 2.91M
- Avg vol
- 1.77M
- EPS
- -0.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 48.64
- High
- 52.87
- Forward P/E
- 9.14
- Beta
- 1.12
- Short ratio
- 5.59
- Inst. own
- 116.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 59.06
- 200-d avg
- 46.62
- 1y target
- 75.21
News
6 hours ago seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
11 hours ago zacks.com
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
11 hours ago marketbeat.com
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its…
11 hours ago zacks.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.
12 hours ago benzinga.com
Travere Therapeutics Q3 2026 Earnings Call Transcript
Travere Therapeutics (NASDAQ:TVTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
14 hours ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
-
14 hours ago benzinga.com
Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.06) by 416.67 percent. This is a 152.54 percent decrease over…
14 hours ago businesswire.com
Travere Therapeutics Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our…
-
1 week ago benzinga.com
Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual…
1 week ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 weeks ago benzinga.com
FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.